Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin
Abstract Background Patients with type 2 diabetes mellitus (T2DM) are characterized by an elevated glycemic index and are at a higher risk for complications such as cardiovascular disease, nephropathy, retinopathy and peripheral neuropathy. Normalization of glycemic index can be achieved by dosing c...
Saved in:
Main Authors: | Robert Dobbins (Author), Elizabeth K. Hussey (Author), Robin O'Connor-Semmes (Author), Susan Andrews (Author), Wenli Tao (Author), William O. Wilkison (Author), Bentley Cheatham (Author), Katare Sagar (Author), Barkate Hanmant (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
by: Mohan V, et al.
Published: (2020) -
Stability indicating thin-layer chromatographic method for estimation of antidiabetic drug Remogliflozin etabonate
by: Dimal A. Shah, et al.
Published: (2021) -
Formulation and evaluation of in situ ophthalmic gel of loteprednol etabonate
by: Shaikh Shoaeba, et al.
Published: (2021) -
Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
by: Timothy L. Comstock, et al.
Published: (2012) -
Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
by: Silvia Tampucci, et al.
Published: (2023)